When patients switch from their current medication to a different medication, the switched products are not covered by insurance reimbursement. This non-reimbursed status of medication switching has been a long-standing issue in South Korea.

The field most impacted is atopic dermatitis. Treatment options had been limited for atopic dermatitis, but various new drugs became available over the past years. New medications, such as interleukin (IL)-inhibitors and JAK inhibitors, have relieved patient burdens, and fortunately, these drugs are listed for reimbursement.

However, an issue related to medication switching recently surfaced. When a patient switches prescriptions to a different med